BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies
Go back to BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 63.94 -1.14 (1.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.08 | 52 Week High | $108.96 | |||
| Open | $65.25 | 52 Week Low | $62.12 | |||
| Day High | $65.29 | P/E | N/A | |||
| Day Low | $63.84 | EPS | $-1.27 | |||
| Volume | 4,455,889 | |||||
